Dr. Eyal Fima
Dr. Fima is special advisor to the CEO of Enlivex (ENLV: Nasdaq) and was the former President & CEO of Enlivex, and has served on its board of directors since March 2014 through October 2018. Previously, from 2005 through 2015, Dr. Fima was Vice President, Product Development, COO and then CEO of PROLOR Biotech. PROLOR Biotech was listed on NYSE in 2010 and then acquired by OPKO Health in 2013 for $560 million, the largest biotech acquisition in the history of Israeli biotech.
Dr. Fima also co-founded NatSpears Ltd., a company specializing in cancer therapeutics, and served as its CEO from 2002 to 2005. Prior to founding NatSpears, Dr. Fima received his Ph.D. from Ben-Gurion University’s Medical School in Israel, and an M.B.A. from the Ben-Gurion University’s Business School.